Effect of α-fluoromethylhistidine, a suicide inhibitor of histidine decarboxylase, on histamine levels in mouse tissues

Abstract

The effects of α-fluoromethylhistidine (α-FMH), a new suicide inhibitor [Kollonitsch et al., Nature, Lond. 274, 906 (1978)], on histidine decarboxylase (HDC) activities and histamine contents of the skin, fundic stomach and brain of mice were investigated. Four hours after i.p. administration of α-FMH to ddy mice, HDC activities in the brain, stomach and skin had decreased in a dose-dependent way (1–25 mg/kg), by a maximum of 90–95%. The histamine levels in the brain and stomach decreased to 50% of the control levels, whereas the level in the skin did not change at all. The time courses of changes in HDC activities and histamine levels were examined. After i.p. administration of 25 mg/kg of α-FMH, HDC activities in these tissues dropped rapidly within 1 hr. Recovery of HDC activities in the stomach and skin began within 12 hr, but the activity in the brain remained low for 24 hr, confirming the result of Garbarg et al. [ J. Neurochem. 35, 1045 (1980)]. The histamine content of the stomach decreased to 40% of the original level in 8 hr and recovered within 12 hr, whereas that in the brain decreased to 50% and remained low for more than 24 hr. The histamine content of the skin did not change. These results suggest that the histamine level that was not reduced by α-FMH was derived from mast cells. During the above experiments, no behavioral changes of the animals were detected. α-FMH prevented the increase in HDC activity in mouse kidney on day 18 of gestation when administered i.p. every 12 hr from day 13. No abnormalities were seen in fetuses and neonates after this treatment. It is concluded that α-FMH causes depletion of newly synthesized histamine in situ and, thus, is useful for studies on histamine.